Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Abstract

DPYD*2A is strongly associated with fluoropyrimidine-induced severe and life-threatening toxicity. DPYD*2A genotype-guided dosing results in adequate systemic drug exposure and significantly improves safety of fluoropyrimidine therapy for the individual patient. On a population level, upfront genotyping seemed cost saving.